导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.84% | 3396/4773 |
| 近一周 | -2.69% | 4157/5465 |
| 近一月 | -2.70% | 1830/5421 |
| 近一季 | 0.33% | 938/5231 |
| 近半年 | -4.45% | 2829/4920 |
| 近一年 | -2.30% | 3036/4394 |
| 近两年 | 31.24% | 2230/2954 |
| 近三年 | 23.61% | 1355/2253 |
| 成立以来 | 212.83% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.13% 3050/4961 |
-5.17% 3544/5312 |
- - |
- - |
| 2025 | 15.56% 2534/4813 |
-0.57% 2307/3635 |
- 2782/4076 |
16.06% 2727/4524 |
0.14% 2186/4813 |
| 2024 | 20.20% 482/3463 |
5.85% 330/2808 |
0.92% 527/3014 |
16.41% 1462/3129 |
-3.34% 2329/3463 |
| 2023 | -3.55% 643/2656 |
5.34% 797/2280 |
-1.19% 452/2385 |
-1.57% 549/2515 |
-5.85% 1526/2655 |
| 2022 | -16.21% 460/2207 |
-12.56% 635/1919 |
6.01% 790/2016 |
-11.07% 489/2113 |
1.64% 1195/2208 |
| 2021 | -8.86% 1059/1822 |
-1.97% 563/1255 |
-1.06% 1157/1330 |
-7.53% 1058/1466 |
1.60% 864/1822 |
| 2020 | 35.46% 414/1250 |
-9.88% 726/1028 |
11.93% 710/1067 |
13.30% 327/1164 |
18.52% 89/1184 |
| 2019 | 40.44% 253/1092 |
23.12% 564/754 |
3.26% 54/804 |
4.08% 219/850 |
6.14% 651/918 |
| 2018 | -19.49% 167/834 |
- - |
- - |
- - |
-12.76% 481/691 |
| 2017 | 42.41% 21/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.35% 107/605 |
- - |
- - |
- - |
- - |
| 2015 | 5.43% 222/575 |
- - |
- - |
- - |
- - |
| 2014 | 48.18% 97/237 |
- - |
- - |
- - |
- - |
| 2013 | -13.09% 164/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 汇丰晋信恒生龙头指数A VS. 长安沪深300非周期A(740101) |